跳至主要内容
临床试验/NCT01894295
NCT01894295Unknown不适用

Assessment Vitamin D Analogues Intake Pathways on the Proteins Which Involved in Metabolic Rate in Obese Subjects

Tehran University of Medical Sciences2 个研究点 分布在 2 个国家目标入组 96 人开始时间: 2012年6月最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
96
试验地点
2
主要终点
Resting Metabolic Rate

研究概览

简要总结

The aim of this double blind clinical trial study is to investigate whether alphacalcidol treatment in obese subjects can affect the resting metabolic rate. Moreover, the investigators will evaluate the pathways of Nesfatin-1, Peroxisome proliferator-activated receptor gamma (PPARγ) and eroxisome proliferator-activated receptor- coactivator-1 α (PGC1α) protein which may lead to change in metabic rate following treatment with either alphacalcidol or placebo.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
22 Years 至 52 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Age 22-52 years Body mass index equal or more than 30

排除标准

  • Acute or chronic inflammatory disease History of hypertension Alcohol or drug abuse History of any condition affecting inflammatory markers Thyroid diseases Malignancies Current smoking Diabetes mellitus Sustained hypertension Heart failure Acute or chronic infections Hepatic or renal diseases Use of PPARγ agonist drug

研究组 & 干预措施

Vitamin D analogue

Experimental

1-α hydroxyvitamin D3; dose 0.25, 0.5 and 1 microgram.

干预措施: Vitamin D analogue (Dietary Supplement)

Placebo

Placebo Comparator

Corn oil pearl Capsules 1 gram

干预措施: Placebo (Dietary Supplement)

结局指标

主要结局

Resting Metabolic Rate

时间窗: Change from baseline to 8 weeks

Measurement by indirect calorimetry.

次要结局

  • Changes of Nesfatin-1, PPARγ and PGC1α protein levels(Change from baseline to 8 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验